<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300363</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-115-NRM</org_study_id>
    <secondary_id>LX4211.115</secondary_id>
    <nct_id>NCT02300363</nct_id>
  </id_info>
  <brief_title>DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin</brief_title>
  <official_title>A Phase 1, Single-center, Open-label, 2-period, Single-sequence, Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose LX4211 on the Pharmacokinetics of Single-dose Rosuvastatin (Crestor®), a Sensitive Breast Cancer Resistance Protein (BCRP) Substrate, in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted as a single-center, open-label, 2-period, single-sequence,&#xD;
      drug-drug interaction study to assess the effects of multiple-dose LX4211 400 mg (2 × 200-mg&#xD;
      tablets qd × 7 days) on the PK of single-dose rosuvastatin (1 × 10-mg tablet) in healthy male&#xD;
      and female subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1-Day 5, Day 13-Day 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure># of Adverse Events</measure>
    <time_frame>Day 1-Day 17</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg oral rosuvastatin administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg oral LX4211 qd administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A (rosuvastatin)</intervention_name>
    <description>10 mg rosuvastatin administered on Day 1 and Day 13</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B (LX4211)</intervention_name>
    <description>400 mg LX4211 administered on Day 7 through Day 13</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)</intervention_name>
    <description>10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects ≥18 to ≤55 years of age&#xD;
&#xD;
          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140&#xD;
             mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm&#xD;
&#xD;
          -  Body mass index (BMI) ≥18 and ≤32 kg/sq m&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant physical, laboratory, or ECG findings that, in the&#xD;
             opinion of the Investigator and/or Sponsor, may interfere with any aspect of study&#xD;
             conduct or interpretation of results&#xD;
&#xD;
          -  Use of any medications or supplements/supratherapeutic doses of vitamins within 14&#xD;
             days prior to the first dose administration and throughout the duration of the study&#xD;
&#xD;
          -  Receipt of any investigational agent or study drug within 30 days prior to Screening&#xD;
&#xD;
          -  Receipt of any protein- or antibody-based therapeutic agents within 3 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Prior exposure to LX4211&#xD;
&#xD;
          -  Use of tobacco, smoking cessation products, or products containing nicotine within 3&#xD;
             months prior to Screening and for the duration of the study&#xD;
&#xD;
          -  History of any serious adverse reaction or hypersensitivity to any inactive component&#xD;
             of LX4211 or rosuvastatin&#xD;
&#xD;
          -  Existence of any surgical or medical condition that might interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of LX4211 or rosuvastatin&#xD;
&#xD;
          -  History of any major surgery within 6 months or anticipated surgery prior to Day&#xD;
&#xD;
          -  History of any clinically significant hypoglycemia or hyperglycemia&#xD;
&#xD;
          -  History of renal disease, or significantly abnormal kidney function test at Screening&#xD;
&#xD;
          -  History of hepatic disease, or significantly abnormal liver function tests at&#xD;
             Screening&#xD;
&#xD;
          -  History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine,&#xD;
             cardiovascular, neurological, hematological, or GI abnormality&#xD;
&#xD;
          -  History of any active infection within 14 days prior to Day 1&#xD;
&#xD;
          -  History of alcohol or substance abuse within 2 years prior to Screening&#xD;
&#xD;
          -  Positive hepatitis panel&#xD;
&#xD;
          -  Donation or loss of &gt;500 mL of blood or blood product within 3 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Women who are breastfeeding or are planning to become pregnant during the study, or&#xD;
             women who have a positive serum pregnancy test&#xD;
&#xD;
          -  Positive urine glucose at Screening&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse and cotinine at Screening, Day -1, or Day 13&#xD;
&#xD;
          -  Inability or difficulty swallowing whole tablets&#xD;
&#xD;
          -  Unable or unwilling to cooperate with the Investigator for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

